BIOCON LTD. - 532523 - Communication To The Shareholders W.R.T. TDS On Final Dividend
Communication to shareholders28-06-2024
28-06-2024
BIOCON LTD. - 532523 - Meeting Conducted With Institutional Investors/ Research Analysts
Meeting conducted with institutional investors/research analysts.28-06-2024
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation27-06-2024
BIOCON LTD. - 532523 - Meeting Conducted With Institutional Investors/ Research Analysts
Meeting conducted with Institutional Investors/ Research analyst26-06-2024
Biocon gets EMA's nod to make biosimilar cancer drug at Bengaluru
Bevacizumab is used to treat colon and rectal cancer, cervical cancer etc24-06-2024
BIOCON LTD. - 532523 - Company Statement Dated June 24, 2024.
EMA approves Biocon Biologics'' New mAbs Facility in India and Renews GMP certifications for India and Malaysia sites.24-06-2024
Biocon Gets Four Observations From US Drugs Regulator For Andhra Facility
The USFDA concluded a GMP inspection of the API facility on June 21, 2024.22-06-2024
Biocon searches for partner to test generic Wegovy, Ozempic in China
Biocon's generics would join at least 15 other generics or biosimilars in development by Chinese drugmakers ahead of an expiry of patent protection on semaglutide20-06-2024